Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to 808.86%.

  • Intellia Therapeutics' EBIT Margin rose 7801000.0% to 808.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 832.16%, marking a year-over-year increase of 4158200.0%. This contributed to the annual value of 923.1% for FY2024, which is 4974100.0% up from last year.
  • As of Q3 2025, Intellia Therapeutics' EBIT Margin stood at 808.86%, which was up 7801000.0% from 772.17% recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' EBIT Margin registered a high of 7297.44% during Q4 2023, and its lowest value of 23997.67% during Q3 2021.
  • Moreover, its 5-year median value for EBIT Margin was 811.07% (2022), whereas its average is 1736.47%.
  • Per our database at Business Quant, Intellia Therapeutics' EBIT Margin crashed by -238712000bps in 2021 and then skyrocketed by 232021700bps in 2022.
  • Over the past 5 years, Intellia Therapeutics' EBIT Margin (Quarter) stood at 625.6% in 2021, then fell by -30bps to 811.07% in 2022, then surged by 1000bps to 7297.44% in 2023, then plummeted by -115bps to 1059.86% in 2024, then grew by 24bps to 808.86% in 2025.
  • Its EBIT Margin was 808.86% in Q3 2025, compared to 772.17% in Q2 2025 and 726.57% in Q1 2025.